Introduction {#s1}
============

RUNX1, RUNX2, and RUNX3, and their common non-DNA-binding partner protein CBFβ, form a small family of heterodimeric transcription factors (TFs) referred to as Core-Binding Factors (CBFs) ([@bib50]). They are best known as master regulators of cell fate determination in blood, bone, and neuron, respectively ([@bib14]). RUNX1 is a master regulator of hematopoietic stem cells and multiple mature blood lineages. Translocations and mutations involving both *RUNX1* and *CBFB* are frequently found in human leukemias ([@bib50]). Recently, key roles of this family of TFs in epithelial cells and solid tumors also started to emerge ([@bib56]; [@bib14]; [@bib46]). In particular, in breast cancer, recent whole-genome and whole-exome sequencing studies have consistently identified point mutations and deletions of *RUNX1* in human luminal breast cancers ([@bib4]; [@bib8]; [@bib15]). In addition, mutations in *CBFB* were also identified in luminal breast cancers from these studies. Its gene product CBFβ is critical for enhancing DNA-binding by RUNX TFs through allosteric regulation ([@bib7]; [@bib55]). Thus, we hypothesized that RUNX1, together with CBFβ, might play a key role in mammary epithelial cell (MEC) lineage determination as a master regulatory TF and that the loss of this normal function might contribute to breast cancer development.

There are two major epithelial cell lineages in the mammary gland (MG), luminal lineage (including ductal and alveolar luminal cells), and basal lineage (the mature cell type in the basal lineage is myoepithelial cell) ([Figure 1A](#fig1){ref-type="fig"}). These two types of MECs are produced by multipotent mammary stem cells (MaSCs, which are basal cells) during embryonic development or upon MEC transplantation to cleared mammary fat pads ([@bib47]; [@bib53]; [@bib51]). In adult MGs, they appear to be maintained by both lineage-specific unipotent stem cells and multipotent basal MaSCs, based on lineage tracing studies ([@bib59]; [@bib58]; [@bib44]; [@bib57]; [@bib62]). The gene regulatory network that must be in place to orchestrate lineage specification and differentiation of stem cells into mature MEC types remains largely elusive, although a number of key TFs have been identified in recent years, for example, GATA3 has been shown as a master regulator for both ductal and alveolar luminal cells ([@bib27]; [@bib1]); ELF5 was identified as a master regulator of alveolar cells ([@bib37]; [@bib13]); SLUG (SNAIL2) was shown as a master regulator of MaSCs, and it could reprogram differentiated MECs to transplantable MaSCs, together with another TF, SOX9 ([@bib17]). In this work, we asked whether RUNX1 is an integral part of this transcription network and how its mutations contribute to breast tumorigenesis. By using genetic, cellular, and molecular approaches, we found that RUNX1 is a key regulator of estrogen receptor (ER)-positive mature ductal luminal cells, and that the loss of *RUNX1* may contribute to the development of ER^+^ luminal breast cancer when under the background of either *TP53* or *RB1* loss.10.7554/eLife.03881.003Figure 1.Expression pattern of *Runx1* in murine MGs.(**A**) Schematic diagram of a simplified version of the MEC hierarchy. MECs can be separated into the luminal and basal lineages. Major MEC subpopulations, their names and name abbreviations, as well as their marker expression patterns are shown. Note: 'luminal progenitor (LP)' has been used to refer to progenitor cells for the luminal lineage defined based on either CD61 ([@bib1]), or CD14 and c-Kit ([@bib2]), or CD49b ([@bib29]; [@bib48]), and is therefore a mixture of overlapping progenitor cell populations and may include common or separate progenitors for ductal and alveolar luminal cells. (**B**) qRT-PCR analysis of *Runx1, Runx2, Runx3*, and *Cbfb* transcripts isolated from luminal and basal cells of adult virgin female mice. (**C**--**H**) IHC staining for RUNX1 on sections of MGs at different developmental stages: (**C**) adult virgin, (**D**--**E**) mid-gestation (the region highlighted in **D** is shown in **E**), (**F**--**G**) lactation (the region highlighted in **F** is shown in **G**), and (**H**) after involution. Arrows and arrowheads indicate RUNX1-expressing luminal and basal cells, respectively; \* indicates lumen. Scale bars = 20 μm. (**I**) Relative expression values of indicated genes determined by microarray analysis of the indicated MEC subpopulations isolated from the MGs of adult virgin female mice. ALs were isolated as YFP^+^ cells from *Wap-Cre;R26Y* females (i.e., MECs genetically marked by the *Wap-Cre* transgene) during mid-gestation. Affymetrix probes used to estimate expression of each indicated gene are 1419555_at, 1422864_at, 1448886_at, 1435663_at, 1449031_at, and 1418496_at for *Elf5*, *Runx1*, *Gata3*, *Esr1*, *Cited1*, and *Foxa1*, respectively. (**J**) *Runx1* expression levels were confirmed in sorted LPs, MLs, and ALs (as in **I**) by qRT-PCR.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.003](10.7554/eLife.03881.003)10.7554/eLife.03881.004Figure 1---figure supplement 1.Expression analysis of *Runx1* and other select luminal transcription factor (TF) genes based on microarray.Relative expression values of indicated genes determined by microarray analysis of the indicated mammary epithelial cell (MEC) subpopulations isolated from the mammary glands (MGs) of adult female mice from multiple published datasets. (**A**) Based on GEO database accession \# GSE40875 (only showing the nulliparous subsets). Basal_CD49hi and Basal_CD49flo are two subpopulations in the lin^−^CD24^lo^Sca1^−^ basal lineage based on higher or lower CD49f expression, respectively. (**B**) Based on GEO database accession \# GSE19446. (**C**) Based on GEO database accession \# GSE20402.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.004](10.7554/eLife.03881.004)

Results {#s2}
=======

*Runx1* is expressed in all MEC subsets except in alveolar luminal cells {#s2-1}
------------------------------------------------------------------------

We first measured expression levels of all three *Runx* genes and their common co-factor gene *Cbfb* in freshly sorted basal epithelial cells (Lin^−^CD24^+^CD29^hi^) and luminal epithelial cells (Lin^−^CD24^+^CD29^lo^) ([Figure 1A](#fig1){ref-type="fig"}) from adult virgin female mice by quantitative RT-PCR (qRT-PCR). Results showed that *Runx1* is the predominantly expressed *Runx* gene in both luminal and basal cells ([Figure 1B](#fig1){ref-type="fig"}). Immunohistochemical (IHC) staining further confirmed the expression of RUNX1 protein in these two major MEC types in adult virgin MGs ([Figure 1C](#fig1){ref-type="fig"}). However, RUNX1 expression is largely absent in alveolar luminal cells (ALs) that start to emerge during pregnancy ([Figure 1D--E](#fig1){ref-type="fig"}). In the lactating gland, the only MEC type that still expresses RUNX1 is the myoepithelial cell ([Figure 1F--G](#fig1){ref-type="fig"}). Upon involution, RUNX1 expression is restored to a pattern resembling that of the virgin gland ([Figure 1H](#fig1){ref-type="fig"}). Additionally, we performed microarray expression profiling of sorted subsets of MECs, including basal cells (Lin^−^CD24^+^CD29^hi^), luminal progenitors (LPs, Lin^−^CD24^+^CD29^lo^CD61^+^), mature luminal cells (MLs, Lin^−^CD24^+^CD29^lo^CD61^−^, mainly represent ductal luminal cells in virgin MGs), and alveolar luminal cells (ALs, i.e., MECs genetically marked by *Wap-Cre* at mid-gestation; *Wap-Cre* is a transgenic mouse line with Cre expression under the control of the *Whey acidic protein* \[*Wap*\] promoter, a milk protein promoter \[[@bib60]\]). Estimation of *Runx1* levels based on this microarray dataset confirmed its expression in all MEC subsets except in ALs ([Figure 1I](#fig1){ref-type="fig"}). We examined *Runx1* expression levels in different subsets of MECs in several additional published microarray datasets ([@bib3]; [@bib33]; [@bib35]) and further confirmed this expression pattern ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}); in particular, in the pregnant MGs, *Runx1* was also found expressed in basal MECs but not in luminal MECs (mainly ALs) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Lastly, by qRT-PCR, we verified that *Runx1* was indeed expressed in sorted LPs and MLs but not in *Wap-Cre*-marked ALs ([Figure 1J](#fig1){ref-type="fig"}).

Loss of *Runx1* in MECs affects multiple MEC subsets {#s2-2}
----------------------------------------------------

The *RUNX1* mutations identified from the recent sequencing studies of human breast cancers include point mutations, frame-shift mutations, and deletions ([@bib4]; [@bib8]; [@bib15]). We analyzed the breast cancer-associated missense mutations of *RUNX1* to determine whether they lead to *loss-of-function* of *RUNX1* ([Figure 2A](#fig2){ref-type="fig"}). Based on a previous alanine-scanning site-directed mutagenesis study ([@bib31]), we found that these missense mutations either affect amino acid residues in RUNX1 that directly contact DNA, or disrupt the overall fold of its DNA-binding RUNT domain or abolish its binding to CBFβ, both of which would also perturb its DNA-binding ([Figure 2B](#fig2){ref-type="fig"}). Thus, similar to *RUNX1* deletions, the point mutations also lead to *loss-of-function* of *RUNX1*, due to disrupted DNA-binding ability. Therefore, we asked whether and how the loss of *Runx1* could affect the development of normal MECs.10.7554/eLife.03881.005Figure 2.Analysis of *RUNX1* mutations.*RUNX1* somatic missense mutations identified in human breast cancers disrupt its DNA-binding either directly (disrupting direct DNA contact) or indirectly (disrupting the overall protein fold of its DNA-binding RUNT domain or disrupting CBFβ binding). (**A**) RUNX1 full-length protein sequence; RUNT domain is highlighted in blue. The three amino acid residues affected by point mutations in luminal breast cancers (based on [@bib15]) are shown in red. Several additional missense mutations (based on [@bib8]; [@bib56]) are also highlighted with red font. (**B**) How these missense mutations affect RUNX1 DNA-binding is predicted based on a previous structural and biochemical analysis of the RUNT domain ([@bib31]).**DOI:** [http://dx.doi.org/10.7554/eLife.03881.005](10.7554/eLife.03881.005)

*Runx1*^*−/−*^ mice died during mid-gestation mainly due to hemorrhages in the central nervous system and are thus not suitable to determine the effect of *Runx1*-loss on MG development ([@bib38]; [@bib63]). We therefore used a conditional knockout allele of *Runx1* (*Runx1*^*L/L*^) ([@bib30]). To facilitate characterization of *Runx1*-null MECs, we bred in a conditional Cre-reporter, *Rosa26-Stop-YFP* (*R26Y*). Cross of the floxed *Runx1* mice with the *R26Y* reporter mice and *MMTV-Cre* transgenic mice allowed us to simultaneously disrupt *Runx1* in MECs and mark the targeted cells by Yellow Fluorescent Protein (YFP) ([Figure 3A](#fig3){ref-type="fig"}). Lineage analysis revealed that in virgin MGs, *MMTV-Cre* mainly targeted MECs in the luminal lineage, but it could also lead to Cre-mediated recombination in a portion of basal MECs ([Figure 3B](#fig3){ref-type="fig"}). By fluorescence-activated cell sorting (FACS), we isolated YFP^+^ MECs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females and *MMTV-Cre;Runx1*^*L/+\ and\ +/+*^*;R26Y* control females and by qRT-PCR, we confirmed the loss of *Runx1* expression in YFP^+^ MECs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females ([Figure 3C](#fig3){ref-type="fig"}). Whole-mount analysis of MGs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females or dams on lactation day-0 did not reveal any obvious gross morphological abnormalities, although a portion (3 out of 7) of *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females exhibited a slight delay in expansion of their ductal trees during pubertal growth ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Surprisingly, however, none of the *MMTV-Cre;Runx1*^*L/L*^*;R26Y* dams were able to successfully nurse their pups ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Most of their pups died within 24 hr postpartum and no milk spots were observed in them compared to pups from *MMTV-Cre;Runx1*^*+/+*(*or\ L/+*)^*;R26Y* dams. A closer examination of MGs of lactating *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females revealed milk stasis and an increasing number of cytoplasmic lipid droplets ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Similar phenotypes have also been observed in *Runx1* conditional knockout mice with *Krt14-Cre* (i.e., Cre-expressing transgenic mice under the control of the *Keratin 14* promoter) (*Krt14-Cre;Runx1*^*L/L*^, data not shown) and in a number of genetically engineered mice with defects in myoepithelial cell contraction and milk ejection ([@bib28]; [@bib40]; [@bib18]; [@bib64]). Since *Runx1* is only expressed in myoepithelial cells at this stage ([Figure 1D--G,I](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}), we reasoned that the nursing defects observed are most likely due to a disrupted function of RUNX1 in myoepithelial cells. Additional studies are required to determine this.10.7554/eLife.03881.006Figure 3.*Runx1*-loss leads to a reduction in the luminal MEC population.(**A**) Schematic representation of the *Runx1* conditional knockout allele in which its exon 4 is flanked by *lox*P sites, as well as the *R26Y* conditional Cre-reporter. STOP: transcriptional *stopper* cassette. Subsequent breeding with *MMTV-Cre* resulted in mice in which selected subsets of MECs express YFP and lack expression of functional RUNX1. (**B**) FACS gating strategy for detecting lin^−^YFP^+^ (lin: lineage markers) MECs, as well as YFP^+^ lin^−^CD24^+^CD29^lo^ luminal (Lu), and lin^−^CD24^+^CD29^hi^ basal (Ba) MECs in *MMTV-Cre;R26Y* females. Str: stromal cells. (**C**) qRT-PCR analysis confirming the loss of *Runx1* expression in YFP^+^ MECs sorted from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (L/L). (**D**) FACS analysis showing the reduced lin^−^YFP^+^ MEC population (left plots), as well as the reduced lin^−^YFP^+^ luminal population (right plots), in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* female compared to those in *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control female. (**E**--**F**) The percentages of lin^−^YFP^+^ MEC population (**E**), as well as the ratios of luminal/basal subpopulations among the lin^−^YFP^+^ gate (**F**), are significantly reduced in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (n = 9) (*L/L*) compared to those in *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females (n = 10) (*+/+*). p values: \*: p ≤ 0.05; error bars represent mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.006](10.7554/eLife.03881.006)10.7554/eLife.03881.007Figure 3---figure supplement 1.Conditional knockout study of *Runx1* in murine MGs.(**A**) Whole-mount carmine staining of inguinal MGs of pubertal (top), adult virgin mice (middle), and lactation day-0 dams (bottom). Scale bars indicate 3 mm. Black arrow indicates the main duct coming from the nipple; \* indicates the lymph node. Blue arrow indicates the distance between the front of the expanding ductal tree and the lymph node (used as a reference point). (**B**) Weaning record showing *MMTV-Cre;Runx1*^*L/L*^ females failed to nurse their pups. (**C**) Hematoxylin and eosin (H&E) staining of sections of MGs from *MMTV-Cre;Runx1*^*+/+*^ (left) and *MMTV-Cre;Runx1*^*L/L*^ (right) dams on lactation day-0. Note the increasing number of cytoplasmic lipid droplets and milk in the lumen of the *MMTV-Cre;Runx1*^*L/L*^ dam. Arrowheads point to lipid droplets.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.007](10.7554/eLife.03881.007)

In *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females, we found that the percentages of the YFP-marked MEC population (representing *Runx1*-null MECs) were significantly reduced when compared to those of the *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females ([Figure 3D--E](#fig3){ref-type="fig"}). Furthermore, the ratios of the YFP-marked luminal to basal subsets were also significantly reduced in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females ([Figure 3D,F](#fig3){ref-type="fig"}); this could be due to an expansion of the YFP-marked basal population or a reduction in the YFP-marked luminal population, or both. However, since the overall population of YFP^+^ MECs in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females was reduced ([Figure 3D--E](#fig3){ref-type="fig"}), the reduction in the YFP^+^ luminal/basal ratio was most likely due to a reduction in the YFP-marked *Runx1*-null luminal population.

Loss of *Runx1* leads to a profound reduction in ER^+^ mature luminal cells {#s2-3}
---------------------------------------------------------------------------

Recent studies suggest that most breast cancers, including both basal-like and luminal subtypes, may originate from luminal cells, rather than from basal MaSCs ([@bib32]; [@bib36]; [@bib42]; [@bib26]). Furthermore, *RUNX1* and *CBFB* mutations have only been found in the luminal subtype of human breast cancers ([@bib4]; [@bib8]; [@bib15]) and our data so far showed that the loss of *Runx1* appeared to lead to a reduction in the luminal population ([Figure 3D--F](#fig3){ref-type="fig"}), we therefore examined the role of RUNX1 in luminal MECs (from which luminal breast cancers may originate).

To determine the overall defects of *Runx1*-null luminal MECs, we first profiled the transcriptomes of YFP^+^ *Runx1*-null luminal cells (sorted from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females) and control YFP^+^ *Runx1*-wild-type (WT) luminal cells (sorted from *MMTV-Cre;Runx1*^*+/+*^*;R26Y*) by microarray. By gene set enrichment analysis (GSEA \[[@bib54]\]), we observed significant enrichment of a previously generated LP signature and downregulation of a ML signature in *Runx1*-null luminal cells ([Figure 4A](#fig4){ref-type="fig"}). These LP and ML signatures were generated previously based on subset-specific genes conserved in the corresponding human and mouse MEC subpopulations ([@bib33]). Furthermore, we also observed significant enrichment of multiple gene sets related to p53 signaling in *Runx1*-null luminal cells in relation to *Runx1*-WT luminal cells ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), possibly indicating a stress response in these mutant luminal cells in vivo. Lastly, we examined the expression levels of a number of TF/co-factor genes known to be part of the transcription network that regulates specification and maintenance of luminal MECs. In our microarray data, we found that *Elf5*, a TF gene critically required in the alveolar cell lineage and a LP marker ([@bib37]; [@bib13]; [@bib33]), was upregulated in *Runx1*-null luminal cells, whereas several ductal luminal TF/co-factor genes (e.g., *Gata3*, *Foxa1*, *Esr1*, *Cited1*) were downregulated ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Among these luminal TF/co-factor genes, *Foxa1* encodes a pioneer factor that is a key determinant of ERα (encoded by *Esr1*) function ([@bib5]; [@bib23]); *Cited1* encodes a selective co-activator for estrogen-dependent transcription, which potentially regulates the sensitivity of luminal cells to estrogen ([@bib65]; [@bib20]). When validated by qRT-PCR, we found that although the expression of *Gata3* did not seem to be significantly affected in luminal cells upon *Runx1*-loss, expression levels of *Foxa1*, *Esr1*, and *Cited1* were downregulated in *Runx1*-null luminal cells, whereas *Elf5* expression was upregulated ([Figure 4B](#fig4){ref-type="fig"}).10.7554/eLife.03881.008Figure 4.*Runx1* disruption leads to a profound reduction in ER^+^ MLs.(**A**) GSEA enrichment plots showing correlation of the expression profiles of *Runx1*-null or WT luminal MECs with previously published conserved human and mouse signatures of LPs (left) or MLs (right) ([@bib33]). (**B**) qRT-PCR validation of TF/co-factor genes known to play roles in luminal lineage specification and maintenance. RNA was isolated from YFP^+^ *Runx1*-null and WT primary luminal MECs. (**C**) FACS plots of expression of CD14 and c-Kit, two LP markers ([@bib2]), in the gated YFP^+^ luminal MECs (Lin^−^CD24^+^CD29^lo^) of adult *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females and *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females. Note the CD14^−^c-Kit^−^ mature luminal (ML) subpopulation was largely lacking in the lower right plot. (**D**) Quantification of the percentages of the ML and LP subpopulations as indicated in **C**, showing significant reduction in the ML subpopulation in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (n = 13) compared to that in *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females (n = 10). (**E**) qRT-PCR analysis showing significantly reduced *Runx1* expression in the LP subpopulation but not in the ML subpopulation in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females. (**F**) FACS plots of expression of CD49b, a LP marker, and Sca1, an ER^+^ ML marker ([@bib48]) in the gated YFP^+^ luminal MEC population. Note the CD49b^−^Sca1^+^ ER^+^ ML subpopulation was dramatically reduced, whereas the CD49b^+^Sca1^−^ ER^−^ LP subpopulation was increased in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females. (**G**) Quantification of the percentages of the ER^+^ ML, ER^+^ LP, and ER^−^ LP subpopulations as indicated in **F**, showing significant reduction in the ER^+^ ML subpopulation in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (n = 4) compared to those in *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females (n = 4). p values: \*: p ≤ 0.05; \#: p ≤ 0.005; \^: p ≤ 0.0005; NS = not significant; error bars represent mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.008](10.7554/eLife.03881.008)10.7554/eLife.03881.009Figure 4---source data 1.(**A**) Gene sets from the MSigDB database C2-CGP (chemical and genetic perturbations, v3.1) enriched in *Runx1*-null luminal cells.(**B**) Gene sets from the MSigDB database C2-CGP (chemical and genetic perturbations, v3.1) enriched in *Runx1*-WT luminal cells. (**C**) Gene sets from the MSigDB database C2-CP:KEGG (KEGG gene sets, v3.1) enriched in *Runx1*-null luminal cells.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.009](10.7554/eLife.03881.009)10.7554/eLife.03881.010Figure 4---figure supplement 1.Analysis of the luminal phenotype in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females.(**A**) GSEA analysis of *Runx1*-null and WT luminal MECs showing enrichment of several gene sets related to the p53 signaling pathway in *Runx1*-null luminal MECs compared to WT luminal MECs. (**B**) Relative expression values of the indicated genes determined by microarray analysis of *Runx1*-null (*Runx1 L/L*) and WT (*Runx1 +/+*) luminal MECs. Affymetrix probes used to estimate expression of each indicated gene are 1448886_at, 1419555_at, 1418496_at, 1449031_at, and 1460591_at for *Gata3*, *Elf5*, *Foxa1*, *Cited1*, and *Esr1*, respectively. (**C**) FACS plots of CD14 and c-Kit expression in the lin^−^ luminal (upper plots) and lin^−^YFP^+^ luminal (bottom plots) MECs of 5-week old *MMTV-Cre;Runx1*^*+/+*^*;R26Y* and *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females showing reduced CD14^−^c-Kit^−^ ML subpopulation within the lin^−^YFP^+^ luminal population in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* female (bottom right plot). (**D**) Quantifications (for **C**) of the percentages of ML or LP subpopulations within the indicated gates showing significantly reduced ML and increased LP subpopulations within the lin^−^YFP^+^ luminal gate in 5-week old *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (n = 4) (L/L) compared to those in 5-week old *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females (n = 4) (+/+). (**E**) FACS plots showing the reduced YFP-marked lin^−^CD29^lo^CD61^−^ ML subpopulation in adult *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females (n = 2) compared to *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females (n = 3). (**F**) Quantifications for the basal, LP and ML subpopulations based on CD61 and CD29 staining in **E**. (**G**) qRT-PCR analysis showing significantly reduced *Runx1* expression in the ER^−^ LP subpopulation, partial *Runx1* reduction in the ER^+^ LP subpopulation, and no reduction in the ER^+^ ML subpopulation from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* (*Runx1 L/L*) females, based on CD49b and Sca1 staining, compared to those from *MMTV-Cre;Runx1*^*+/+*^*;R26Y* (*Runx1 +/+*) control females. p values: \^: p ≤ 0.0005; NS = not significant; error bars represent mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.010](10.7554/eLife.03881.010)

Our microarray data for the entire luminal population suggested that *Runx1*-loss in luminal MECs might lead to either a global block in luminal differentiation or loss of a mature luminal MEC subpopulation. To determine this, we performed FACS analysis of the Lin^−^CD24^+^CD29^lo^ luminal lineage. Intriguingly, we found that in both pubertal and adult virgin *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females, the YFP^+^ *Runx1*-null ML subpopulation defined based on CD14 and c-Kit staining (Lin^−^CD24^+^CD29^lo^CD14^−^c-Kit^−^, referred to as CD14^−^c-Kit^−^ MLs hereafter) ([@bib2]) was significantly reduced, whereas the YFP^+^ *Runx1*-null LP subpopulation (Lin^−^CD24^+^CD29^lo^CD14^+^c-Kit^+^, referred to as CD14^+^c-Kit^+^ LPs hereafter) was increased ([Figure 4C--D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}). The reduction in the ML subpopulation was further confirmed in adult virgin *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females based on CD61 staining (MLs: Lin^−^CD29^lo^CD61^−^) ([@bib1]) ([Figure 4---figure supplement 1E--F](#fig4s1){ref-type="fig"}).

The residual YFP^+^ MECs in the ML gate in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females could either represent a truly *Runx1*-null ML subpopulation (but reduced in percentage) or represent YFP-marked MLs that have escaped Cre-mediated disruption of the *Runx1*^*L*^ allele (thus not truly *Runx1*-null). To determine this, we sorted YFP^+^ CD14^−^c-Kit^−^ MLs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females and *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females; as an internal control, we also sorted YFP^+^ CD14^+^c-Kit^+^ LPs from the same animals. By qRT-PCR, we found that while *Runx1* expression in YFP^+^ LPs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females was significantly reduced, its expression in YFP-marked MLs was only slightly reduced ([Figure 4E](#fig4){ref-type="fig"}). This data suggested that many YFP^+^ MLs in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females might have escaped Cre-mediated excision in at least one copy of their *Runx1*^*L*^ alleles (thus they were either *Runx1*^*+/+*^ or *Runx1*^*+/−*^). The data thus also suggests that RUNX1 is essential for the emergence or maintenance of the ML lineage.

A recent study demonstrated that the luminal cell compartment of the mouse MG could be further resolved into non-clonogenic ER^+^ MLs, as well as clonogenic ER^+^ LPs and ER^−^ LPs based on CD49b and Sca1 staining; the ER^+^ LPs may represent progenitors for ER^+^ MLs whereas the ER^−^ LPs probably represent alveolar progenitors ([@bib48]). We examined these luminal subpopulations in the YFP-gated luminal population in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* virgin females. We found that compared to their corresponding subpopulations in *MMTV-Cre;Runx1*^*+/+*^*;R26Y* control females, the CD49b^−^Sca1^+^ ER^+^ ML subpopulation was significantly reduced in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females, whereas the CD49b^+^Sca1^−^ ER^−^ LP subpopulation was significantly increased; the CD49b^+^Sca1^+^ ER^+^ LP subpopulation was not significantly altered ([Figure 4F--G](#fig4){ref-type="fig"}). Of note, since the overall YFP^+^ luminal population was significantly reduced in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females ([Figure 3D--F](#fig3){ref-type="fig"}), the increase in the ER^−^ LP subpopulation might be mainly due to a reduction in the ER^+^ ML subpopulation (thus proportionally increased the percentage of the ER^−^ LP subset), rather than a significant expansion of ER^−^ LPs per se; similarly, although the percentage of the ER^+^ LP subpopulation was not significantly changed, the absolute number of YFP^+^ ER^+^ LPs could still be reduced (due to an overall reduction in YFP^+^ luminal MECs). In support of this, we measured *Runx1* expression in these three luminal MEC subpopulations. We found that whereas the YFP-marked ER^−^ LP subset had a profound reduction in *Runx1* expression, the YFP^+^ ER^+^ LP subset exhibited a partial reduction in *Runx1* transcripts, and the YFP^+^ ER^+^ ML subpopulation had almost no loss of *Runx1* expression ([Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}), suggesting RUNX1 is required for both ER^+^ LPs and ER^+^ MLs. Collectively, our data suggest that RUNX1 is required for the development or maintenance of the ER^+^ luminal lineage, and it is particularly essential for the ER^+^ MLs.

Reduction in the ER^+^ luminal subpopulation upon *Runx1* disruption can be rescued by the loss of either *Trp53* or *Rb1* {#s2-4}
--------------------------------------------------------------------------------------------------------------------------

From recent whole-genome/exome sequencing studies, *RUNX1* and *CBFB* mutations were only identified in the luminal subtype of human breast cancers ([@bib4]; [@bib8]; [@bib15]), which are typically ER^+^. Paradoxically our data so far in the murine model suggest that *loss-of-function* of *Runx1* leads to a reduction in ER^+^ luminal MECs in vivo. Furthermore, we have followed *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females for at least 18 months and have not observed any mammary tumor development in them. This can be explained by a possibility in which *RUNX1*-mutant breast cancer originates from ER^+^ luminal MECs and *Runx1* disruption alone actually leads to the loss of the cell-of-origin of such cancer. We hypothesized that additional genetic events might be needed to cooperate with *RUNX1*-loss to promote the development of luminal breast cancer from ER^+^ luminal MECs.

Interestingly, one recent sequencing study unveiled that pathway signatures of *RB1* mutation, *TP53* mutation, and *RUNX1* mutation are co-associated with human luminal B breast tumors ([@bib15]). Furthermore, by carefully examining luminal breast cancer cases with *RUNX1* mutations, we noticed that \>50% of them are accompanied by mutations or deletions in either *TP53* or *RB1* genes ([@bib8]). Lastly, our microarray data for luminal MECs suggested that loss of *Runx1* might lead to activation of the p53 pathway in luminal cells in general ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Based on these observations, we hypothesized that loss of *Runx1* in luminal MECs perturbs the fate of ER^+^ MLs, possibly leading to a stress response and subsequently upregulation of the p53 pathway, which then triggers cell cycle arrest (or apoptosis); this would cause the *Runx1*-null (YFP^+^) MLs to be outcompeted by *Runx1*-WT (YFP^−^) MLs. If this is the case, then either disruption of the p53 pathway or activation of cell cycle by *Rb1*-loss might rescue the phenotype of ER^+^ ML cell loss upon *Runx1* disruption. To test this, we bred *MMTV-Cre;Runx1*^*L/L*^*;R26Y* mice to *Trp53* or *Rb1* conditional knockout mice (*Trp53*^*L/L*^ or *Rb1*^*L/L*^). In the resulting compound mice, we were only able to follow *MMTV-Cre;Runx1*^*L/L*^*;Trp53*^*L/L*^*;R26Y* or *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* females for ∼4--5 months or ∼9--10 months, respectively, due to lethality possibly caused by hematopoietic malignancies (as *MMTV-Cre* has leaky expression in bone marrow hematopoietic cells). Nevertheless, we were able to analyze MEC subpopulations in their MGs. Upon *MMTV-Cre*-induced *Trp53* or *Rb1* loss alone, the percentages of YFP-marked MECs increased dramatically so that the majority of MECs in their MGs became YFP^+^ ([Figure 5A](#fig5){ref-type="fig"}, increased from ∼20--30% to ∼70--90%), suggesting a growth advantage for *Trp53*-null or *Rb1*-null MECs (in relation to their *Trp53*-WT or *Rb1*-WT YFP^−^ neighbors). However, the percentages of the YFP-marked luminal population were both reduced ([Figure 5A](#fig5){ref-type="fig"}, middle and bottom left plots compared to upper left plot, green circles). Interestingly, disruption of *Runx1* either together with *Trp53* or with *Rb1* significantly increased the percentages of the YFP^+^ luminal population ([Figure 5A--C](#fig5){ref-type="fig"}, increased from ∼4% \[*Trp53*-loss alone\] to ∼11% \[*Runx1*/*Trp53*-loss\] \[[Figure 5B](#fig5){ref-type="fig"}\] and from ∼12% \[*Rb1*-loss alone\] to ∼23% \[*Runx1*/*Rb1*-loss\] \[[Figure 5C](#fig5){ref-type="fig"}\], respectively). Of particular note, the percentage of the YFP-marked ML subpopulation, which was dramatically reduced upon *Runx1*-loss alone ([Figure 5A](#fig5){ref-type="fig"}, upper right plot, red circle), was reverted back to almost the normal level upon simultaneous loss of *Runx1* together with either *Trp53* or *Rb1* ([Figure 5A](#fig5){ref-type="fig"}, middle right plot for *Trp53* \[*5B* for quantification\], bottom right plot for *Rb1* \[*5C* for quantification\], red circles). To verify the presence of ER^+^ MECs in the MGs of these compound female mice, we performed IHC staining for ERα and could indeed detect abundant ERα^+^ luminal MECs in both *MMTV-Cre;Runx1*^*L/L*^*;Trp53*^*L/L*^*;R26Y* and *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* compound females ([Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}, since the majority of MECs in their MGs were YFP^+^, most of these ERα^+^ MECs should represent MECs with simultaneous loss of *Runx1* and *Trp53* or *Rb1*). As the residual YFP^+^ MECs in the ML gate from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (*Runx1*-loss alone) appear to have escaped Cre-mediated excision in at least one *Runx1*^*L*^ allele ([Figure 4E](#fig4){ref-type="fig"}), we wanted to determine whether YFP^+^ MLs in these compound mice had undergone (or escaped) Cre-mediated excision of their *Runx1*^*L*^ alleles. By qRT-PCR analysis, we observed more than 50% reduction in the *Runx1* expression level in the YFP-marked ML subpopulation sorted from *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* females ([Figure 5D](#fig5){ref-type="fig"}), suggesting a significant portion of these YFP^+^ MLs should have undergone biallelic excision of their *Runx1*^*L*^ alleles.10.7554/eLife.03881.011Figure 5.Reduction in ER^+^ MLs upon *Runx1* disruption can be rescued by *Trp53* or *Rb1* loss.(**A**) FACS analysis showing total lin^−^YFP^+^ MEC population, lin^−^YFP^+^ luminal population, and lin^−^YFP^+^ ML and LP subpopulations (from left to right for each genotype, an example of the gating strategy is indicated in the bottom left plots) in female mice with the indicated genotypes. Those highlighted in green show increased lin^−^YFP^+^ luminal populations upon the loss of both *Runx1* and *Trp53* or *Rb1* (middle and bottom right plots, respectively) compared to those of *Trp53* or *Rb1* loss alone (middle and bottom left plots, respectively); those highlighted in red show increased lin^−^YFP^+^ ML subpopulations upon the loss of both *Runx1* and *Trp53* or *Rb1* (middle and bottom right plots, respectively) compared to that of *Runx1*-loss alone (upper right plot). Lu: luminal; Ba: basal; LP: luminal progenitor; ML: mature luminal cell. (**B**--**C**) Quantifications for the percentages of each indicated subpopulation in **A** under either the *Trp53*-loss (**B**) or *Rb1*-loss background (**C**); in (**B**) *Trp53*-loss alone (n = 5), *Trp53/Runx1*-loss (n = 3); in (**C**) *Rb1*-loss alone (n = 5), *Rb1/Runx1*-loss (n = 5). (**D**) qRT-PCR analysis showing significantly reduced *Runx1* expression in both the YFP-marked ML and LP subpopulations in *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* females. p values: \*: p ≤ 0.05; \^: p ≤ 0.0005; NS = not significant; error bars represent mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.011](10.7554/eLife.03881.011)10.7554/eLife.03881.012Figure 5---figure supplement 1.Abundant ER^+^ MECs are present in both *Runx1/Trp53*-null and *Runx1/Rb1*-null MGs.(**A**--**B**) IHC staining for ERα showing abundant ER^+^ MECs (brown cells) in *MMTV-Cre;Runx1*^*L/L*^ females upon simultaneous loss of either *Trp53* (**A**) or *Rb1* (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.03881.012](10.7554/eLife.03881.012)

RUNX1 controls transcription of select target genes in vitro {#s2-5}
------------------------------------------------------------

Since *Runx1*-loss leads to a reduction in ER^+^ MLs and the residual MECs present in the CD14^−^c-Kit^−^ or CD49b^−^Sca1^+^ ML gate appear to have escaped Cre-mediated disruption of *Runx1* ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), it is technically challenging to study how RUNX1 controls the fate of ER^+^ luminal cells at the molecular level in this mouse model directly. Therefore, we first performed molecular studies in human breast cancer cell lines MCF7 and T47D. Although both cell lines are ER^+^ luminal breast cancer cell lines, a key difference between them at the molecular level is that MCF7 cells express WT p53, whereas T47D cells carry a *TP53* missense mutation (nonfunctional p53) ([@bib45]). Interestingly, despite multiple attempts, we were only able to obtain *RUNX1* knockdown (kd) stable lines from *TP53*-mutant T47D cells but not from *TP53*-WT MCF7 cells. This observation suggests that a similar genetic interaction between *RUNX1*-loss and *TP53*-loss may also operate in human ER^+^ luminal breast cells. We therefore used T47D cells as our cell line model to study how RUNX1 controls the fate of ER^+^ luminal breast epithelial cells. By Western blot, we found that upon *RUNX1* kd, the protein level of ELF5 was increased, whereas the protein levels of both ERα and FOXA1 were reduced, and CITED1 protein level appeared unchanged ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.03881.013Figure 6.RUNX1 controls transcription of select target genes in human ER^+^ breast cancer cells.(**A**) Western blot showing upregulation of ELF5 and downregulation of ERα and FOXA1 upon RUNX1 knockdown (kd) in T47D luminal breast cancer cells. (**B**) ChIP analysis showing significant binding of RUNX1 to multiple ECRs (evolutionarily conserved regions) with RUNX-binding sites in the *ELF5* locus in T47D cells. (**C**) ChIP analysis showing significant binding of RUNX1 to the −1.6 kb and −1.9 kb regions of *FOXA1* in T47D cells. RUNX1-binding to the −1.4 kb region is marginally significant (p = 0.08). In (**B**--**C**), RUNX1-binding motifs (highlighted in red) and their flanking sequences are shown; note RUNX1-binding motifs in ECR-1 and ECR-3 of *ELF5* (**B**) are in the reverse strand. p values: \*: p ≤ 0.05; \#: p ≤ 0.005; NS = not significant; error bars represent mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.013](10.7554/eLife.03881.013)10.7554/eLife.03881.015Figure 6---figure supplement 1.Opposite expression patterns of RUNX1 and ELF5 proteins upon alveolar differentiation of HC11 cells.Western blot showing downregulation of RUNX1 and upregulation of ELF5 protein levels upon induced alveolar differentiation in HC11 cells.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.015](10.7554/eLife.03881.015)

ELF5 is a master regulator of alveolar cells, a cell type in which *Runx1* is not expressed ([Figure 1D--J](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Interestingly, it was shown previously that *RUNX1* is a direct target of ELF5 and is repressed by it, based on chromatin immunoprecipitation (ChIP) analysis ([@bib25]). In our microarray data for sorted MEC subsets, as well as those publicly available microarray datasets we analyzed, we could always observe a largely opposite expression pattern of *Elf5* and *Runx1* ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In both basal cells and MLs in which *Runx1* is highly expressed, *Elf5* is not; *Elf5* expression is greatly elevated in ALs whereas *Runx1* expression is repressed. This negative correlation in their expression levels could be further confirmed in the HC11 cell line model. While both *Runx1* and *Elf5* were expressed in uninduced HC11 cells, upon induction of alveolar differentiation, the ELF5 protein level was increased, whereas the RUNX1 protein level was reduced ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To determine whether *ELF5* is also a direct target of RUNX1, we performed ChIP analysis on T47D cells and identified significant binding of RUNX1 to multiple evolutionary conserved RUNX-binding sites in the *ELF5* locus ([Figure 6B](#fig6){ref-type="fig"}). The RUNX1-binding was particularly profound in an enhancer region ∼17 kb upstream of the *ELF5* transcription start site (ECR-1, [Figure 6B](#fig6){ref-type="fig"}).

Since *RUNX1* kd in T47D cells led to downregulation of ERα and FOXA1 ([Figure 6A](#fig6){ref-type="fig"}), we asked whether *ESR1* (encoding ERα) and *FOXA1* are direct targets of RUNX1. We identified a RUNX-binding motif in the *ESR1* control region ∼1.4 kb upstream of its transcription start site, as well as several RUNX-binding motifs in the *FOXA1* control region ∼1.4--1.9 kb upstream of its transcription start site. By ChIP assay, we confirmed significant binding of RUNX1 to the −1.6 kb and −1.9 kb motifs in the *FOXA1* locus ([Figure 6C](#fig6){ref-type="fig"}). Collectively, these data suggest that *FOXA1* and *ELF5* genes may be direct targets of RUNX1 positively and negatively regulated by it, respectively.

RUNX1 represses *Elf5* and regulates mature luminal TF/co-factor genes involved in the ER program in vivo {#s2-6}
---------------------------------------------------------------------------------------------------------

To determine whether RUNX1 regulates the expression of these transcription regulators in primary cells in vivo, we took advantage of the rescue of *Runx1*-null ER^+^ luminal MECs by *Trp53* or *Rb1*-loss ([Figure 5](#fig5){ref-type="fig"}) and measured expression of these genes in FACS-sorted YFP^+^ luminal MEC subsets. We used *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* double mutant and *MMTV-Cre;Rb1*^*L/L*^*;R26Y* single mutant females for this analysis, as *MMTV-Cre;Runx1*^*L/L*^*;Trp53*^*L/L*^*;R26Y* double mutant females often exhibit early lethality. When comparing double mutants (with *Rb1/Runx1*-loss) to single mutants (with *Rb1*-loss alone), we found that both *Elf5* and *Esr1* appeared upregulated in ER^+^ LPs and ER^+^ MLs (based on CD49 and Sca1 staining) from double mutants ([Figure 7A--B](#fig7){ref-type="fig"}, left plots), and *Foxa1* and *Cited1* were downregulated in the rescued double mutant ER^+^ MLs ([Figure 7B](#fig7){ref-type="fig"}, left plot). Since we cannot rule out a possibility in which *Rb1*-loss in MECs also affects expression of these genes, we compared their expression in double mutants to matched WT females as well. From this comparison, we found that both *Elf5* and *Esr1* were also upregulated and *Foxa1* and *Cited1* were slightly downregulated in ER^+^ LPs and ER^+^ MLs from double mutants ([Figure 7A--B](#fig7){ref-type="fig"}, right plots). Furthermore, as we showed above, in *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females, although the YFP-marked ER^+^ MLs appeared to have escaped Cre-mediated disruption of the *Runx1*^*L*^ allele, the YFP-marked ER^+^ LP subset did exhibit a partial reduction in *Runx1* expression ([Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}). We therefore asked whether there is any correlation of reduced *Runx1* expression to changes in expression of other genes in this MEC subset. Interestingly, we found that in *Runx1*-mutant ER^+^ LPs both *Elf5* and *Esr1* were upregulated and *Foxa1* and *Cited1* also appeared slightly upregulated ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}).10.7554/eLife.03881.016Figure 7.Target genes of RUNX1 in ER^+^ luminal MECs revealed by in vivo expression analysis.(**A**--**B**) qRT-PCR analysis showing changes in expression of the indicated genes in sorted YFP^+^ ER^+^ LPs (**A**) and ER^+^ MLs (**B**) (based on CD49b and Sca1 expression) from 4- to 5-month old *MMTV-Cre;Rb1*^*L/L*^*;Runx1*^*L/L*^*;R26Y* double mutant females, compared to those from either *MMTV-Cre;Rb1*^*L/L*^*;R26Y* single mutant females (left plots) or *MMTV-Cre;R26Y* WT females (right plots). (**C**--**D**) qRT-PCR analysis comparing expression of the indicated genes in CD14^−^c-Kit^−^ MLs (**C**) and CD14^+^c-Kit^+^ LPs (**D**) from 7-month to 2-month old *MMTV-Cre;Rb1*^*L/L*^*;Runx1*^*L/L*^*;R26Y* double mutant and *MMTV-Cre;Rb1*^*L/L*^*;R26Y* single mutant (control) females. Expression was normalized to those of the corresponding 2-month old double or single mutant females, respectively. Error bars: mean ± S.E.M.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.016](10.7554/eLife.03881.016)10.7554/eLife.03881.017Figure 7---figure supplement 1.Loss of *Runx1* in vivo leads to changes in expression of ER program-related genes.(**A**) Changes in expression of the indicated genes in the ER^+^ LP subpopulation from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females (*Runx1 L/L*) compared to *MMTV-Cre;Runx1*^*+/+*^*;R26Y* WT females (*Runx1 +/+*). (**B**) *Elf5* expression is de-repressed upon *Runx1*-loss in all ER^−^ MEC subsets examined, including CD49b^+^Sca1^−^ ER^−^ LPs, CD14^+^c-Kit^+^ LPs enriched for ER^−^ cells (both sorted from *MMTV-Cre;R26Y* females) and ER^−^ basal MECs (sorted from *Krt14-Cre;R26Y* females). (**C**) Compared to ER^+^ LPs shown in **A**, *Esr1* expression is not increased in CD49b^+^Sca1^−^ ER^−^ LPs, CD14^+^c-Kit^+^ LPs (enriched for ER^−^ cells), and ER^−^ basal MECs with *Runx1*-loss. Note *Esr1* expression in CD14^+^c-Kit^+^ LPs with *Runx1*-loss is slightly elevated, possibly due to the fact that a small portion of CD14^+^c-Kit^+^ LPs are ER^+^ LPs ([@bib48]), which exhibit ostensibly higher *Esr1* expression, as shown in **A**.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.017](10.7554/eLife.03881.017)10.7554/eLife.03881.018Figure 7---figure supplement 2.RUNX1 reduction leads to hyperproliferation of abnormal ER^+^ luminal cells in a context-dependent manner.(**A**) Quantification of the percentages of the ER^−^ LP, ER^+^ LP, and ER^+^ ML subpopulations sorted from *MMTV-Cre;Rb1*^*L/L*^*;Runx1*^*L/L*^*;R26Y* females (n = 4) compared to those from *MMTV-Cre;Rb1*^*L/L*^*;R26Y* control females (n = 4) showing slight upregulation of the ER^+^ LP and ER^+^ ML subpopulations from *MMTV-Cre;Rb1*^*L/L*^*;Runx1*^*L/L*^*;R26Y* females. (**B**) Knockdown (kd) of *RUNX1* in T47D luminal breast cancer cells, which carry a *TP53* mutation, increased their proliferation. (**C**--**D**) Quantification of IHC staining for ERα showing significant increase in the numbers of ER^+^ luminal MECs in *MMTV-Cre;Rb1*^*L/L*^*;Runx1*^*L/L*^*;R26Y* (**C**) and *MMTV-Cre;Trp53*^*L/L*^*;Runx1*^*L/L*^*;R26Y* (**D**) double mutant females compared to their corresponding single mutant control females. (**E**) qRT-PCR analysis showing expression of indicated genes in the ER^−^ LP, ER^+^ LP, and ER^+^ ML subpopulations from *MMTV-Cre;R26Y* WT females. Expression was normalized to that of the ER^+^ LP subpopulation (=1). p values: \*: p ≤ 0.05; \#: p ≤ 0.005; \^: p ≤ 0.0005; error bars represent mean ± S.E.M. (error bars represent mean ± S.D. in **B**).**DOI:** [http://dx.doi.org/10.7554/eLife.03881.018](10.7554/eLife.03881.018)

Thus, from both cell line and in vivo expression analyses, the gene that exhibits the most consistent change upon *Runx1*-loss is *Elf5*, which appears to be a target gene of RUNX1 repressed by it in ER^+^ luminal MECs. Intriguingly, we found that upregulation of *Elf5* upon *Runx1* disruption is not restricted to ER^+^ luminal cells and/or the *Rb1*-loss genetic background. In LPs defined based on either CD14^+^c-Kit^+^ or CD49b^+^Sca1^−^ where *Elf5* is abundantly expressed, loss of *Runx1* further increased their *Elf5* expression ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Strikingly, in basal MECs where *Elf5* is normally not expressed ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), loss of *Runx1* led to its profound upregulation ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). These data suggest that in normal MGs, RUNX1 represses expression of *Elf5* in almost all MEC subsets in which *Runx1* is expressed.

Our in vivo data showed that *Esr1* is upregulated rather than downregulated (based on the in vitro data in T47D cells, [Figure 6A](#fig6){ref-type="fig"}) in ER^+^ luminal MECs upon *Runx1*-loss. This is most likely due to hyperproliferation of *Runx1*-null ER^+^ luminal MECs under the *Rb1* (or *Trp53*)-null background, rather than de-repression of *Esr1* expression caused by *Runx1*-loss. Several lines of evidence support this notion. First, in *Runx1/Rb1*-double mutant females, we not only observed a slight increase in the percentages of total YFP^+^ MECs ([Figure 5A](#fig5){ref-type="fig"}) but also an increase in both the YFP^+^ luminal subset and, in particular, the YFP-marked ER^+^ LP and ER^+^ ML subpopulations ([Figure 5A--C](#fig5){ref-type="fig"}, [Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). In *TP53*-mutant T47D cells, we found that kd of *RUNX1* leads to a significant increase in their proliferation ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}). Furthermore, we quantified ERα^+^ luminal MECs in MGs with either *Runx1/Rb1*-loss or *Runx1/Trp53*-loss and found that both double mutants contained significantly more ERα^+^ MECs than single *Rb1*-loss or *Trp53*-loss mutants ([Figure 7---figure supplement 2C--D](#fig7s2){ref-type="fig"}). Since our expression analysis was based on FACS-sorted MEC subsets (e.g., LP, ML) and each subset may represent a mixture of both ER^+^ and ER^−^ MECs (with different proportions), a change in this proportion, due to overrepresentation of the rescued ER^+^ luminal cells in the FACS-sorted MEC subpopulations from *Rb1/Runx1*-null double mutants, may contribute to the ostensibly higher *Esr1* transcript signals in double mutant ER^+^ LPs and ER^+^ MLs ([Figure 7A--B](#fig7){ref-type="fig"}). Lastly, we found that *Esr1* upregulation in vivo appears restricted to the *Runx1*-null ER^+^ luminal MECs; in ER^−^ LPs and ER^−^ basal MECs, we did not observe upregulation of *Esr1* expression upon *Runx1* disruption ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). This is apparently different from negative regulation of *Elf5* by RUNX1, in which loss of *Runx1* leads to expression of *Elf5* even in basal cells in which *Elf5* is normally not expressed ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). This is also different from a recent finding of repression of *Esr1* by ID4, as loss of *Id4* leads to widespread upregulation of *Esr1* expression in both luminal and basal MECs ([@bib6]). Collectively, these data suggest that *Esr1* is not a direct target repressed by RUNX1 in vivo; the downregulation of ERα in vitro in T47D cells upon *RUNX1* kd is likely to be indirect (e.g., due to *RUNX1* loss-induced upregulation of *ELF5*, as overexpression of *ELF5* in T47D cells can also suppress ERα expression \[[@bib25]\]).

The higher *Esr1* signal makes it challenging to accurately quantify any potential changes in expression levels of ER-related mature luminal genes upon *Runx1* disruption, by simply comparing their expression in double to single mutants or to WT controls (as the matched MEC subsets based on FACS sorting may have different cell compositions, if *Runx1*-null ER^+^ luminal MECs become over-populated). Interestingly, we noticed that in YFP^+^ MLs from *MMTV-Cre;Runx1*^*L/L*^*;Rb1*^*L/L*^*;R26Y* females, *Runx1* reduction became more profound in older females. We therefore similarly monitored changes in expression of other TF/co-factor genes over time in animals with the same genotype. This strategy may allow us to control for gene expression changes introduced by differences in cell populations or genetic backgrounds. By using this strategy, we found that in *Rb1*-null single mutants (controls), *Esr1*, *Foxa1*, and *Cited1* were upregulated and *Elf5* was downregulated in their YFP^+^ CD14^−^c-Kit^−^ MLs when they aged; however, in YFP^+^ MLs from double mutants, following *Runx1* reduction, although *Esr1* was upregulated to a similar level (to that of single mutants), *Foxa1* and *Cited1* were not, and *Elf5* was even further upregulated ([Figure 7C](#fig7){ref-type="fig"}). We also observed a similar trend of changes for *Foxa1*, *Cited1*, and *Elf5* in YFP^+^ CD14^+^c-Kit^+^ LPs from the same animals ([Figure 7D](#fig7){ref-type="fig"}). Of note, *Esr1* expression in these LPs appeared further upregulated in older females, possibly due to hyperproliferation of the rescued ER^+^ luminal cells within this largely ER^−^ LP subpopulation (the LP subset defined based on CD14^+^c-Kit^+^ contains a small number of ER^+^ cells \[[@bib48]\]). Overall, the data from this time course study further supports that in ER^+^ luminal cells, RUNX1 negatively and positively regulates the expression of *Elf5* and mature luminal TF/co-factor genes (e.g., *Foxa1* and *Cited1*), respectively.

As shown above, in YFP^+^ ER^+^ LPs from *MMTV-Cre;Runx1*^*L/L*^*;R26Y* females with partial *Runx1* reduction, we observed an abnormal expression pattern of these TF/co-factor genes (i.e., upregulation of both *Elf5* and *Esr1* and slight upregulation of *Foxa1* and *Cited1*, [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). This may be explained by a possibility in which a portion of them are committed for differentiation to ER^+^ MLs by upregulating *Esr1*; however due to *Runx1*-loss, *Elf5* is not repressed and *Foxa1* is not sufficiently upregulated in them, potentially leading to an abnormal population of *Elf5*^+^*Esr1*^high^*Foxa1*^low^*Cited1*^low^ ML-like cells retained in the ER^+^ LP FACS gate. A small number of such abnormal *Runx1*-null ER^+^ ML-like cells may also be present in the ML FACS gate. These abnormal luminal MECs may be the target cells rescued for proliferation under the *Rb1*-loss background, and their hyperproliferation may contribute to the unusual *Elf5*^+^*Esr1*^high^*Foxa1*^low^*Cited1*^low^ expression pattern ([Figure 7C--D](#fig7){ref-type="fig"}). As a further support to this notion, we measured expression levels of these TF/co-factor genes in the ER^−^ LP, ER^+^ LP, and ER^+^ ML subsets sorted from WT animals and found that *Elf5* expression trends down, whereas expression of *Esr1*, *Foxa1*, and *Cited1* similarly trends up, from ER^−^ LPs to ER^+^ LPs and then to ER^+^ MLs, and that *Runx1* expression is also elevated from ER^+^ LPs to ER^+^ MLs ([Figure 7---figure supplement 2E](#fig7s2){ref-type="fig"}). This expression pattern suggests that differentiation of ER^+^ luminal MECs requires coordinated expression of these factors and *Runx1*-loss may disrupt their coordinated expression.

Collectively, our in vitro and in vivo expression analyses coupled with ChIP analysis suggest that *Elf5* is a key target gene of RUNX1 repressed by it in MECs. RUNX1 also positively regulates the expression of mature luminal TF/co-factor genes involved in the ER program and among them, *Foxa1* is a direct target of RUNX1, and RUNX1 does not appear to regulate transcription of *Esr1* directly.

Discussion {#s3}
==========

Among TFs that control cell fates of the two subpopulations of luminal MECs, GATA3 has been shown as a common master regulator for both ER^+^ ductal luminal cells and ER^−^ alveolar luminal cells ([@bib27]; [@bib1]), whereas ELF5 has been identified as a key regulatory TF specific for the alveolar luminal subset ([@bib37]; [@bib13]). However, what is the TF that specifically controls the fate of the ER^+^ ductal luminal subset remained largely elusive. In this study, we identified RUNX1 as a key regulator of ER^+^ luminal MECs. RUNX1 controls the in vivo fate of this luminal subpopulation by repressing the program for an alternative cell fate choice (i.e., repressing the key TF gene for alveolar cells, *Elf5*) and by optimizing activation of the ML gene expression program (i.e., regulating key mature luminal TF/co-factor genes such as *Foxa1*) ([Figure 8A](#fig8){ref-type="fig"}). Loss of *Runx1* impairs the fate of ER^+^ luminal cells, leading to a profound reduction in this luminal subpopulation. However, the loss of either *Trp53* or *Rb1* can rescue this defect, leading to hyperproliferation of *Runx1*-mutant ER^+^ luminal cells, which may eventually progress to ER^+^ luminal breast cancer, upon acquisition of additional mutations ([Figure 8B](#fig8){ref-type="fig"}). Our study thus provides a direct link between a somatically mutated lineage-specific TF, impaired cell fate, and development of luminal breast cancer.10.7554/eLife.03881.019Figure 8.Model for the role of RUNX1 in ER^+^ mammary luminal cells and luminal breast cancer.(**A**) Relative expression levels of key TFs in different subsets of MECs are indicated ('+++', '++', '+', '±', '−' indicate highest to low to no expression, based on \[[Figure 1I](#fig1){ref-type="fig"}\] and our single cell profiling data for sorted MECs \[MPAvB and ZL, unpublished data\]). RUNX1 or ELF5 controls the ductal or alveolar luminal cell fate, respectively, by antagonizing each other. RUNX1 further controls the fate of ER^+^ ductal luminal MECs by regulating the ER program via modulating FOXA1 expression. (**B**) Genetic interaction between the loss of *RUNX1* and the loss of either *TP53* or *RB1* plays a key role in the development of *RUNX1*-mutant ER^+^ luminal breast cancer.**DOI:** [http://dx.doi.org/10.7554/eLife.03881.019](10.7554/eLife.03881.019)

Among RUNX1 target genes, the repressed *Elf5* is of particular interest, as it encodes a master regulatory TF for the alternative cell fate of the milk-secreting alveolar lineage in which *Runx1* is not expressed ([Figure 1D--G,I--J](#fig1){ref-type="fig"}). We showed that *ELF5* is a direct target of RUNX1 and is repressed by it ([Figures 6A--B and 7](#fig6 fig7){ref-type="fig"}). Thus, combined with the previous observation in which *RUNX1* was reciprocally shown as a direct target repressed by ELF5 ([@bib25]), these data suggest that RUNX1 and ELF5 are two master regulators for mutually exclusive cell fate choices (i.e., ductal vs alveolar fates) by antagonizing each other\'s transcription program (e.g., RUNX1 promotes the ER program \[this study\], whereas ELF5 suppresses it \[[@bib25]\]) ([Figure 8A](#fig8){ref-type="fig"}) in a way similar to the GATA1-PU.1 paradigm for regulating the choice between erythroid and myeloid fates ([@bib22]).

Intriguingly, RUNX1 not only represses *Elf5* expression in ER^+^ luminal cells but also in all other MEC subsets in which *Runx1* is expressed ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). The de-repression of *Elf5* in basal MECs may also be of clinical relevance. Recently it was found that RUNX1 protein expression correlates with poor prognosis in ER^−^ breast cancer and more specifically in triple-negative breast cancer (TNBC) ([@bib16]). Furthermore, *RUNX1* was also found associated with super-enhancers in an ER^−^ breast cancer cell line ([@bib19]). As super-enhancers often associate with key oncogenes in cancer cells ([@bib34]), these recent findings suggest that RUNX1 may also play an oncogenic role in ER^−^ breast cancers. The link between *RUNX1* and *ELF5* in basal MECs may explain a potential oncogenic role of RUNX1 in ER^−^ breast cancer/TNBC, as it was shown previously that *SNAI2* (encodes SLUG) is a target of ELF5 repressed by it ([@bib9]). Thus, it is possible that RUNX1 expression in ER^−^ breast cancer cells may repress *ELF5* expression, leading to de-repression (thus upregulation) of *SNAI2* expression, which then promotes epithelial-mesenchymal transition (EMT) and aggressiveness of breast cancer cells. Interestingly, it was shown recently that *Snai2*-null mice exhibit a nursing defect, due to failed milk ejection caused by defects in basal/myoepithelial cell differentiation ([@bib39]). In *Runx1*-null mice, upregulation of *Elf5* in basal MECs may lead to repression of *Snai2*, which may provide an explanation for the similar nursing defect we have observed in our *Runx1* conditional knockout mice ([Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}).

In luminal breast cancer, our study provides strong evidence to support that RUNX1 plays a key role in this breast cancer subtype as a tumor suppressor in ER^+^ ductal luminal cells, which may be their cells of origin. All three RUNX TFs have been shown to play context-dependent roles in breast cancer development as either tumor suppressors or oncogenes ([@bib12]). Among them, RUNX3 is also a tumor suppressor as it is often inactivated in human breast cancers and loss of one copy of *Runx3* led to spontaneous mammary tumor development in a portion of aged female mice ([@bib21]). The tumor suppressor role of RUNX3 in breast cancer is explained by its ability to inhibit ERα-dependent transactivation by reducing the stability of ERα ([@bib21]). In contrast, RUNX2 mainly exhibits oncogenic roles in breast cancer by promoting invasiveness and metastasis via its target, *SNAI2* ([@bib10]); however it may also play a tumor suppressor role in breast cancer by antagonizing ERα (thus, similar to RUNX3) ([@bib11]). In this study, we showed that RUNX1, the most abundantly expressed RUNX TF in MECs, controls the fate of ER^+^ luminal cells in part by upregulating *FOXA1* and repressing *ELF5*. Furthermore, RUNX1 has also been shown as a novel tethering factor for recruiting ERα to its genomic sites for ER-mediating transcriptional activation ([@bib52]). Estrogen signaling has dual roles in MECs and breast cancer cells; on one hand it has an oncogenic role by promoting proliferation of ER^+^ luminal breast cancer cells, on the other hand it also has a tumor suppressor role by promoting MEC differentiation and inhibiting metastasis of breast cancer cells ([@bib12]). The tumor suppressor role of RUNX2 and RUNX3 mainly relates to the antagonism between RUNX2/3 and the cancer-promoting program of ER signaling, whereas the tumor suppressor role of RUNX1 largely correlates to its ability to positively regulate the tumor-suppression program of ER signaling. The tumor suppressor role of RUNX1 is also consistent with a previous observation in which *RUNX1* was found among a 17-gene signature associated with metastasis as a gene downregulated in metastasis-prone solid tumors, including breast cancer ([@bib43]).

Lastly, our study also provides an explanation for the paradox in which RUNX1 is a positive regulator of the ER program, yet its *loss-of-function* mutations and deletions are only present in ER^+^ human luminal breast cancers (often accompanied by mutations or copy number losses in *TP53* or *RB1* genes) ([@bib8]; [@bib15]). We show that the loss of *Runx1* does not appear to affect transcription of *Esr1* directly (thus, the affected luminal cells remain phenotypically ER^+^) but may lead to a crippled ER program, in part due to de-repression of *Elf5* and insufficient upregulation of *Foxa1*, which may reduce the sensitivity and output of ER signaling, respectively ([@bib23]; [@bib25]). The impaired ER program in *Runx1*-mutant ER^+^ luminal cells may cause cellular stress, leading to activation of the p53 pathway and subsequently cell cycle arrest and/or apoptosis; as a result, abnormally differentiated *Runx1*-mutant ER^+^ luminal cells are outcompeted by their WT neighbors in vivo. However, the loss of *Trp53* or *Rb1* can relieve the cell cycle arrest or positively activate cell cycle, respectively, and/or rescue apoptosis in them, leading to rescue of the *Runx1*-mutant ER^+^ luminal cells. In humans, upon acquisition of additional mutations, the *RUNX1/TP53*-mutant or *RUNX1/RB1*-mutant ER^+^ premalignant luminal cells may progress to ER^+^ luminal breast cancer, upon acquisition of additional oncogenic events ([Figure 8B](#fig8){ref-type="fig"}). Of note, germline mutations of *RUNX1* that result in haploinsufficiency of RUNX1 can lead to an autosomal dominant disorder referred to as familial platelet disorder with a propensity to acute myeloid leukemia (FPD/AML) ([@bib49]). Interestingly, in one study that characterized three FPD/AML pedigrees, it was found that one female patient with FPD/AML also developed a breast cancer 2 years after AML was diagnosed, and no other tumors were observed in all three pedigrees ([@bib41]). Although the sample size for this study was too small, it certainly raises an intriguing question as to whether germline mutations of *RUNX1* predispose FPD/AML patients to luminal breast cancer, but only under a background of either *TP53* or *RB1* loss.

In summary, we identified RUNX1 as a key regulator of the ER^+^ luminal lineage. Loss of *RUNX1* may contribute to the development of ER^+^ luminal breast cancer under a background of either *TP53* or *RB1* loss and upon cooperation with other additional oncogenic events.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

Mice carrying the floxed *Runx1* allele (*Runx1*^*L/L*^) ([@bib30]) were bred with mice carrying a conditional Cre-reporter, *R26Y*. Subsequently, these mice were bred with mice that drive expression of Cre recombinase under the control of the mouse mammary tumor virus (*MMTV*) promoter (*MMTV-Cre*) and with mice carrying the floxed *Trp53* allele (*Trp53*^*L/L*^) or floxed *Rb1* allele (*Rb1*^*L/L*^). For studying *Runx1* disruption in basal MECs, Cre transgenic mice under the control of the *Keratin 14* promoter (*Krt14-Cre*) were also used. Mice were obtained from JAX (*R26Y*: 006148; *MMTV-Cre*: 003553) or the MMHCC repository (*Krt14-Cre*: 01XF1; *Wap-Cre*: 01XA8) or were a generous gift from Dr Stuart Orkin (*Trp53*^*L/L*^ and *Rb1*^*L/L*^ \[[@bib61]\]). All animal experiments and procedures were approved by our Institutional Animal Care and Use Committee (IACUC).

Whole-mount, histology, and immunohistochemistry {#s4-2}
------------------------------------------------

Whole-mounts of MGs of pubertal, adult virgin, or lactation day-0 mice were fixed and processed as previously described ([@bib24]). For histology and immunohistochemical staining, MGs were fixed in 10% formalin and embedded in paraffin. For RUNX1 or ERα detection, antigen retrieval (Citrate buffer pH 6.0, 20 min boil in microwave oven) was performed prior to incubation with an anti-RUNX1 antibody (2593-1, Epitomics, Burlingame, CA) or an anti-ERα antibody (SC-542, Santa Cruz Biotechnology, Dallas, TX). Signal was detected using the impress reagent kit and DAB substrate (MP-7401 and SK-4100, Vector Laboratories, Burlingame, CA).

Mammary gland cell preparation, flow cytometric analysis, and cell sorting {#s4-3}
--------------------------------------------------------------------------

Thoracic and inguinal mammary glands were dissected from pubertal or adult virgin female mice and cell suspensions were prepared as previously described ([@bib47]). Flow cytometric analysis was performed with a DXP11 analyzer (Cytek, Fremont, CA) or an Accuri C6 analyzer (BD Biosciences, San Jose, CA). FACS sorting was performed with a FACSAria sorter (BD Biosciences). Data were analyzed with FlowJo (Tree Star, Ashland, OR) or CFlow (BD Biosciences). Antibodies used for FACS were purchased from eBiosciences (San Diego, Ca) and included CD24-eFluor450, CD24-eFluor605, CD29-APC, CD61-PE, c-Kit-PE-CY7, CD14-PE, CD49b-PE, Sca1-APC and biotinylated CD31, CD45, and TER119 (i.e., lineage \[Lin\] markers), as well as Streptavidin-PerCP-CY5.5. We also used a Sca1-APC-CY7 antibody purchased from BD biosciences (San Jose, CA).

Microarray analysis and quantitative RT-PCR {#s4-4}
-------------------------------------------

Total RNA from sorted subsets of MECs was prepared by the RNeasy kit (Qiagen, Valencia, CA) and amplified with the Ovation RNA Amplification System V2 (Nugen, San Carlos, CA). YFP-marked luminal cells were sorted from adult virgin *MMTV-Cre;Runx1*^*L/L*^*;R26Y* or *MMTV-Cre;Runx1*^*+/+*^*;R26Y* littermates. Normal MEC subsets, including MaSCs, LPs, and MLs, were sorted from WT C57/B6 adult virgin females; alveolar luminal cells (ALs) were sorted as YFP^+^ cells from *Wap-Cre;R26Y* females at mid-gestation. Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA) was used to generate the expression profiles. All arrays were normalized by dCHIP and analyzed by GSEA as described ([@bib54]), using MSigDB database v3.1 (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>). For qRT-PCR, cDNA was generated with Omniscript (Qiagen) according to the manufacture\'s protocol and real-time PCR was performed using FastStart SYBR Green Master (Roche, Indianapolis, IN). ΔΔCt method was used for normalization to the control group and to the endogenous control (*Hprt*). Primers are listed in [Supplementary file 1](#SD2-data){ref-type="supplementary-material"}.

ChIP analysis {#s4-5}
-------------

Cells were cross-linked with 1% formaldehyde at room temperature for 10 min, quenched with 0.125 M glycine for 5 min and washed with PBS, harvested by scraping and lysed in cell lysis buffer (0.1% SDS; 0.5% NP40; 1 mM EDTA; 10 mM Tris--HCl, pH 7.4; 0.5% NaDOC). 200--1000 bp DNA fragments were obtained after sonication. After 10 min centrifugation at max speed at 4°C, supernatant was used for IP overnight at 4°C. 30 μl Dynabeads Protein G beads (Invitrogen, Carlsbad, CA) and 1 μg antibody were used for each IP. One tenth of lysate was saved as input. The following antibodies were used: rabbit anti-RUNX1 (ab92336, Abcam, Cambridge, MA), rabbit IgG (sc-2027, Santa Cruz Biotechnology). The beads were washed twice with the following buffers, 3 min each: low-salt buffer (0.1% SDS; 1% Triton X-100; 1 mM EDTA; 10 mM Tris--HCl, pH 7.4; 300 mM NaCl; 0.1% NaDOC), high-salt buffer (0.1% SDS; 1% Triton X-100; 1 mM EDTA; 10 mM Tris--HCl, pH 7.4; 500 mM NaCl; 0.1% NaDOC), LiCl buffer (10 mM Tris--HCl, pH 8; 0.25M LiCl; 1 mM EDTA, pH 8; 1% NP-40; 1% NaDOC), and TE. Precipitated materials were eluted with 300 μl elution buffer (1% SDS; 0.1 M NaHCO3; 50 mM Tris--HCl, pH 8; and 10 mM EDTA). Chromatin was reverse-cross-linked by adding 12 μl of 5 M NaCl and incubated overnight at 65°C. DNA was obtained after RNaseA treatment, protease K treatment, phenol/chloroform extraction, and ethanol precipitation. DNA was analyzed by qPCR, normalized to the input DNA. Primers are listed in [Supplementary file 1](#SD2-data){ref-type="supplementary-material"}.

*RUNX1* knockdown, Western blot, and proliferation assay {#s4-6}
--------------------------------------------------------

shRNAs for *RUNX1* were purchased from Open Biosystems (Huntsville, AL; shRNA sequences are listed in [Supplementary file 1](#SD2-data){ref-type="supplementary-material"}, data from a pool of TRCN0000013659-D1 and TRCN0000013662-D4 were shown). After lentiviral infection and puromycin selection, stable shRNA-expressing cell lines were generated. For Western blotting, whole-cell extracts were prepared by boiling cells for 10 min at 95°C in SDS sample buffer (50 mM Tris \[pH 6.8\]; 100 mM DTT; 2% SDS; 0.1% bromophenol blue; 10% glycerol). Cell lysates were then resolved by SDS-PAGE. β-actin (Fisher Lab, Hampton, NH) was used as a loading control. Primary antibodies (RUNX1: Abcam ab92336, ELF5: Abcam ab77007, CITED1: Abcam ab92550, ERα: Santa Cruz Biotechnology sc-8002, FOXA1: Santa Cruz Biotechnology sc-6553) were detected using HRP-conjugated anti-rabbit antibodies and visualized using enhanced chemiluminescence detection (ECL reagents from Fisher Lab). Proliferation of T47D cells was determined by absorbance of alamarBlue, following manufacturer\'s protocol (Invitrogen Lot155363SA). 1 × 10^5^ cells were seeded in a 96-well plate and were measured after 3 or 5 days in culture. 1/10 volume of alamarBlue reagent was directly added to cells in culture medium, incubated for 4 hr at 37°C. Absorbance of alamarBlue was monitored at 570 nm, using 600 nm as a reference wavelength (normalized to the 600 nm value).

Statistical analysis {#s4-7}
--------------------

The results were reported as mean ± S.E.M. unless otherwise indicated, and Student\'s *t* tests were used to calculate statistical significance.

Accession numbers {#s4-8}
-----------------

The microarray expression profiling datasets generated in this manuscript have been deposited to the GEO database under the following accession numbers: GSE47375 (for Runx1) and GSE47376 (for normal MEC subsets) or as SuperSeries GSE47377.
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Major dataset
-------------

The following datasets were generated:

van BragtMP, LiZ, 2013,Microarray expression profiling study of Runx1-null and wild type luminal mammary epithelial cells,GSE47375;<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47375>,In the public domain at GEO: <http://www.ncbi.nlm.nih.gov/geo/>.

van BragtMP, LiZ, 2013,Microarray expression profiling of distinct subsets of mouse mammary epithelial cells,GSE47376;<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47376>,In the public domain at GEO: <http://www.ncbi.nlm.nih.gov/geo/>.

The following previously published datasets were used:

Meier-AbtF, ThiryS, RoloffT, Bentires-AljM, 2013,Early parity-induced gene expression in mouse mammary cell subtypes,GSE40875;<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40875>,In the public domain at GEO: <http://www.ncbi.nlm.nih.gov/geo/>.

SmythGK, WuD, LimE, VisvaderJE, LindemanGJ, 2010,Gene expression profiles of normal mouse mammary cell subpopulations FACS sorted based on expression of biomarkers,GSE19446;<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19446>,In the public domain at GEO: <http://www.ncbi.nlm.nih.gov/geo/>.

SmythGK, WuD, Asselin-LabatM, LindemanGJ, VisvaderJE, 2010,Mouse mammary epithelial cell subpopulations from pregnant and virgin mice,GSE20402;<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20402>,In the public domain at GEO: <http://www.ncbi.nlm.nih.gov/geo/>.

10.7554/eLife.03881.021

Decision letter

Fuchs

Elaine

Reviewing editor

Rockefeller University

,

United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells" for consideration at *eLife*. Your article has been favorably evaluated by Fiona Watt (Senior editor), a Reviewing editor, and 3 reviewers.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This manuscript was submitted over a year ago, and after full review it was rejected by *eLife*. In that paper, the expression and role of Runx1 in mammary gland development and lineage formation was analyzed, and it was shown that Runx1 is expressed in most of the mammary lineages, and its knockout via MMTV-Cre and K14-Cre affects lactation. The authors showed that the number of mature ductal luminal cells (ML) is decreased while their progenitors upstream (luminal progenitor LP) are increased in Runx1 null relative to wild type (WT) controls. The authors concluded that Runx1 must play a role in mature luminal ductal cell formation and that its loss blocks differentiation. From there, the authors tried to understand the mechanisms of Runx1 action and found that in luminal cells the cells associated with LP are increased and the genes associated with ML are decreased. Moreover they showed by ChIP in a cancer cell line (MCF7) that Runx1 is bound to the promoters of Cited 1 (a ML gene) and Elf5 (a LP gene). These genes have been previously studied and the phenotypes described seem to match with the role uncovered here for Runx1, suggesting that Runx1 is directly targeting these genes *in vivo*.

The reviewers felt that in the first submission, the paper brought novel insight into the developmental role of Runx1 in breast biology, and felt that the association with breast cancer was intriguing. However, they also felt that the paper required significant editing and delineated specific suggestions to revise it. Additionally, the reviewers felt that neither the developmental nor the cancer side of the paper were sufficiently strong and necessitated experimental bolstering. The reviewers required more experiments to bolster these stories, including providing more statistical analyses and details of the methodology.

Two of the initial reviewers felt that the paper has changed significantly in the last year, and that the revised version is now much better focused. That said, none of the reviewers felt that the revised version is without problems. Since the paper was an initial rejection, and since the revised work is now quite different from the initial version, the reviewers and managing editor made the decision to treat this as a new submission.

The reviewers agree that since the only ML YFP+ cells detected are ones that still express Runx1, the authors are able to conclude that Runx1 is needed intrinsically for the formation of the ER+ ML lineage. The reviewers were also impressed by the authors\' discovery that they discovered that the mutations found in human ER+ breast cancer are actually null mutations, as they liked their sleuthing that suggests that the cells most likely (not unequivocal) the origin of these types of cancer mutations require Runx1 in some way. The fact that the authors were able to rescue the phenotype with RbKO and p53KO makes a compelling link with cancer. These findings were deemed the strongest and a reasonable case for further consideration by *eLife*.

That said, the reviewers remain unconvinced by the transcriptional mechanisms provided, and do not feel that the authors have provided a compelling case for Runx1 being a master regulator of the luminal lineage. Although carrying out ChIP-seq analyses on *in vivo* material seems beyond the scope of current technology for the mammary epithelial field, RNA-seq or microarray on purified populations of *in vivo* material still seems within the grasp of what can be reasonable to request. The authors argue that they can\'t do this because the residual YFP-marked MECs in the ML gate are not truly Runx1-null MLs. And the population of LPs is a mixed population of progenitors for either alveolar luminal or ductal luminal cells. Therefore, they don\'t have evidence that the YFP-marked LPs are progenitors upstream of MLs in the luminal differentiation hierarchy and are blocked in differentiation to ER+ MLs. I agree that this poses a hurdle but it still does not address the caveat that at present the data are restricted to culture studies with a cell line. The authors are encouraged to explore other possible Cre lines in an effort to bolster the *in vivo* expression data. The inducible KO line does not have to be lineage-specific if coupled with cell surface markers to be used soon after the induction. The authors should expect to see the genes downregulated in the LP cells before the numbers of ML cells actually change. The data as they presently stand could be misleading.

If the authors fail to rectify this point, one alternative would be to remove or shorten and tone down the mechanistic data on how Runx1 regulates other transcription, and then look a bit more closely on how RB/p53 and Runx1 interact. Another possibility would be to look in the p53null Runx1nullYFP+ cells and explore their defects, if any. If these cells appear as normal ML cells, this would suggest that the Runx1 null defect is in proliferation/survival of the ML precursors. RB and p53 may not be directly related to the differentiation phenotype and the targets shown, but rather to survival with loss of function mutants. Even with only a small fraction of ML cells being knocked out efficiently in the p53null Runx1null or RBnull Runx1 null double mutant, if the authors can see Runx1 down in this mixed fraction, then they should be able to see other genes changed that came up in their *in vitro* data. They could at least try qRT-PCR, instead of microarray, on the genes they think are essential from *in vitro* data, and then see whether these genes are changed in the double mutant. This would strengthen their conclusions.

The authors either need to molecularly link this to differentiation or overcome the hurdles for bolstering the *in vitro* data with *in vivo* gene expression data. It would seem that one of these two avenues might be successful, which is needed to clear the path to publishing in *eLife*.
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Author response

*The reviewers remain unconvinced by the transcriptional mechanisms provided, and do not feel that the authors have provided a compelling case for Runx1 being a master regulator of the luminal lineage. Although carrying out ChIP-seq analyses on in vivo material seems beyond the scope of current technology for the mammary epithelial field, RNA-seq or microarray on purified populations of in vivo material still seems within the grasp of what can be reasonable to request. The authors argue that they can\'t do this because the residual YFP-marked MECs in the ML gate are not truly Runx1-null MLs. And the population of LPs is a mixed population of progenitors for either alveolar luminal or ductal luminal cells. Therefore, they don\'t have evidence that the YFP-marked LPs are progenitors upstream of MLs in the luminal differentiation hierarchy and are blocked in differentiation to ER+ MLs. I agree that this poses a hurdle but it still does not address the caveat that at present the data are restricted to culture studies with a cell line. The authors are encouraged to explore other possible Cre lines in an effort to bolster the in vivo expression data. The inducible KO line does not have to be lineage-specific if coupled with cell surface markers to be used soon after the induction. The authors should expect to see the genes downregulated in the LP cells before the numbers of ML cells actually change. The data as they presently stand could be misleading*.

We agree that an inducible Cre line \[e.g., *K8-CreER* for luminal mammary epithelial cells (MECs)\] combined with the *Runx1* conditional knockout allele (*Runx1*^*L*^) and a conditional Cre-reporter \[e.g., *Rosa26-Stop-YFP (R26Y)*\] may allow us to characterize early molecular changes upon induced *Runx1* disruption in ER^+^ luminal MECs. However, this would require extensive mouse breeding in order to put multiple alleles together in the same mouse; therefore it was not feasible for us to use this approach to obtain new *in vivo* data within two months or an even longer time window. We therefore decided to still focus on our existing *MMTV-Cre*-based mouse models and performed extensive *in vivo* expression analysis using sorted MEC subsets from these animals.

*If the authors fail to rectify this point, one alternative would be to remove or shorten and tone down the mechanistic data on how Runx1 regulates other transcription, and then look a bit more closely on how RB/p53 and Runx1 interact. Another possibility would be to look in the p53null Runx1nullYFP+ cells and explore their defects, if any. If these cells appear as normal ML cells, this would suggest that the Runx1 null defect is in proliferation/survival of the ML precursors. RB and p53 may not be directly related to the differentiation phenotype and the targets shown, but rather to survival with loss of function mutants. Even with only a small fraction of ML cells being knocked out efficiently in the p53null Runx1null or RBnull Runx1 null double mutant, if the authors can see Runx1 down in this mixed fraction, then they should be able to see other genes changed that came up in their in vitro data. They could at least try qRT-PCR, instead of microarray, on the genes they think are essential from in vitro data, and then see whether these genes are changed in the double mutant. This would strengthen their conclusions*.

We have mainly followed this suggestion to obtain our *in vivo* expression data for genes that have already been tested in our initial cell culture model. Our main strategy was to monitor levels of *Runx1* reduction in different subsets of MECs sorted from our *MMTV-Cre*-based conditional knockout mice and then to determine whether there was any correlation of changes in expression of other genes to reduced *Runx1* expression. Took advantage of the rescue of *Runx1*-null ER^+^ luminal MECs by Rb1-loss, we performed expression analysis in the rescued ER^+^ LPs and ER^+^ MLs from the *Rb1/Runx1*-null mice (we did not perform this experiment in *p53/Runx1*-null mice as they exhibited early lethality, which prohibited us from obtaining enough animals for expression analysis). In addition, we also performed expression analysis for these genes in the ER^+^ LP subset from the *Runx1* conditional knockout mice (*MMTV-Cre;Runx1*^*L/L*^*;R26Y*), as ER^+^ LPs may represent the precursor population for ER^+^ MLs and our new *Runx1* expression analysis data shows that this population has partial *Runx1* reduction ([Figure 4--figure supplement 1G](#fig4s1){ref-type="fig"}). These *in vivo* expression analysis data are presented in several new figures, including [Figure 7](#fig7){ref-type="fig"}, [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"} and [Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}, and are described in a new sub-section in the main text.

Below is a summary of key findings from our new expression analysis experiments:

A\) Consistent with our *in vitro* data, we also obtained strong *in vivo* data to demonstrate that *Elf5* is a key target gene repressed by RUNX1. In addition to its repression by RUNX1 in ER^+^ luminal MECs, we found *Elf5* is repressed by RUNX1 in almost all other MEC subsets (including basal MECs) in which *Runx1* is expressed. The de-repressed expression of *Elf5* in basal cells also allows us to provide an explanation for the nursing defects observed in our *Runx1* conditional knockout mice (via a potential *Runx1-Elf5-Snail2* link in basal/myoepithelial cells). Since the main focus of this paper is to determine the role of RUNX1 in ER^+^ luminal MECs and luminal breast cancer, we did not pursue this further (but this certainly opens a new avenue for a future study).

B\) Unexpectedly, from our *in vivo* expression analysis, we found that *Esr1* is upregulated in ER^+^ luminal MECs. This is very different from our previous *in vitro* data in T47D cells in which we observed a reduction in ERα level upon *RUNX1* knockdown. Although we showed previously that RUNX1 binds to a RUNX1-binding motif ∼1.4kb upstream of the *ESR1* transcription start site, this binding is relatively weak (∼3-fold enrichment). We repeated the ChIP analysis for this site, as well as for all the other sites we tested previously for *ELF5*, *FOXA1* and *CITED1*. By applying statistical analysis, we found that while RUNX1 binding to the control regions of *ELF5*, *FOXA1* and *CITED1* is all statistically significant, its binding to the -1.4kb site of *ESR1* is [not]{.ul} significant. Although we cannot rule out RUNX1 binding to other sites in the *ESR1* locus, all these data suggest that RUNX1 may not regulate transcription of *ESR1* directly. The downregulation of ERα in T47D cells upon *RUNX1* knockdown is most likely indirect \[e.g., due to *RUNX1*-loss-induced upregulation of *ELF5*, as overexpression of *ELF5* in T47D cells can also suppress ER expression ([@bib25])\]. To explain why *Esr1* appears upregulated *in vivo* upon *Runx1* reduction, we discussed several possibilities and in particular, we provided evidence to support that the observed *Esr1* upregulation may be in part due to hyperproliferation of the rescued *Runx1*-null ER^+^ luminal MECs (i.e., more *Esr1*-expressing cells present in a sorted MEC subpopulation compared to the same subpopulation from control mice).

C\) We provided evidence to support that *Foxa1* and *Cited1* are target genes of RUNX1. *Runx1*-loss reduces their expression levels but does not abolish their expression entirely. Their downregulation is more profound in the rescued *Runx1*-null ER^+^ MLs (new [Figure *7B-C*](#fig7){ref-type="fig"}), the subpopulation of luminal MECs that is affected by *Runx1*-loss the most. To strengthen this conclusion, we used multiple normalization approaches (i.e., normalized to *Rb1*-null single mutant control mice, to wild type control mice, and to younger mice with the same genotype) to control for gene expression changes introduced by differences in cell populations and/or genetic backgrounds.

*The authors either need to molecularly link this to differentiation or overcome the hurdles for bolstering the in vitro data with in vivo gene expression data. It would seem that one of these two avenues might be successful, which is needed to clear the path to publishing in* eLife*.*

Our new *in vivo* expression data, combined with our previous observations, allow us to propose the following revised model: In the ER^+^ luminal lineage, RUNX1 is mainly required during differentiation from ER^+^ LPs to ER^+^ MLs (this is also the stage during which *Runx1* expression is notably elevated, [Figure 7--figure supplement 2E](#fig7s2){ref-type="fig"}, new data). Loss of *Runx1* leads to abnormally differentiated ER^+^ MLs (i.e., *Elf5*^+^*Esr1*^high^*Foxa1*^low^*Cited1*^low^ ML-like cells, due to de-repression of *Elf5* and insufficient upregulation of *Foxa1* and *Cited1*, all of which may impair the sensitivity and/or output of the ER program). This molecular defect may cause cellular stress and subsequently activation of the p53 pathway in these abnormal cells, leading to cell cycle arrest and/or apoptosis; as a result, abnormally differentiated *Runx1*-null ER^+^ luminal cells are outcompeted by their wild type neighbors *in vivo*. However, loss of p53 or Rb1 would relieve the cell cycle arrest or positively activate cell cycle, respectively, and/or rescue apoptosis in them, leading to rescue of these abnormal ER^+^ ML-like cells. Upon acquisition of additional mutations, these *Runx1/p53*-mutant or *Runx1/Rb1*-mutant ER^+^ premalignant luminal cells eventually progress to ER^+^ luminal breast tumors. We believe this revised model has provided important *in vivo* mechanistic advances to better explain why and how *loss-of-function* of *RUNX1* leads to development of ER^+^ luminal breast cancer specifically.

[^1]: These authors contributed equally to this work.
